[go: up one dir, main page]

AR003134A1 - Uso de compuestos de 2-fenil-3-benzoil-benzotiofeno y de sales farmaceuticamente aceptables de los mismos para reducir el nivel de perdidasoseas, asociadas con la administracion de estrogenos. - Google Patents

Uso de compuestos de 2-fenil-3-benzoil-benzotiofeno y de sales farmaceuticamente aceptables de los mismos para reducir el nivel de perdidasoseas, asociadas con la administracion de estrogenos.

Info

Publication number
AR003134A1
AR003134A1 ARP960102930A AR10293096A AR003134A1 AR 003134 A1 AR003134 A1 AR 003134A1 AR P960102930 A ARP960102930 A AR P960102930A AR 10293096 A AR10293096 A AR 10293096A AR 003134 A1 AR003134 A1 AR 003134A1
Authority
AR
Argentina
Prior art keywords
pharmaceutically acceptable
compounds
phenyl
acceptable salts
benzotiophene
Prior art date
Application number
ARP960102930A
Other languages
English (en)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of AR003134A1 publication Critical patent/AR003134A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Uso de los compuestos de 2-fenil-3-benzoil benzotiofeno de la fórmula (II) donde R1 es independientemente -H, -OH, -O(C1-4 alquilo), -OCO-alquilo -OCOC6H5ó -OSO2 (C4-C6 alquilo); y R2 es 1-piperidinilo, 1-pirrolidinilo, metil-1- pirrolidinilo,dimetil-1-pirrolidinilo, 4-morfolino, dimetilamino, dietilaminoo hexametilenoimino y sales farmacéuticamente aceptables de los mismos, caracterizado porque comprende la preparación de medicamentos útiles parareducir al mínimo los efectos del a pérdida ósea cuando se administran compuestos de fórmula (I) donde R es -CH2CON(CH3)-n-CH2-CH2CH2CH3 ó -SO(CH2)3CF2CF3, ó una sal farmacéuticamente aceptable del mismo.
ARP960102930A 1995-06-06 1996-06-05 Uso de compuestos de 2-fenil-3-benzoil-benzotiofeno y de sales farmaceuticamente aceptables de los mismos para reducir el nivel de perdidasoseas, asociadas con la administracion de estrogenos. AR003134A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US47111195A 1995-06-06 1995-06-06

Publications (1)

Publication Number Publication Date
AR003134A1 true AR003134A1 (es) 1998-07-08

Family

ID=23870302

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP960102930A AR003134A1 (es) 1995-06-06 1996-06-05 Uso de compuestos de 2-fenil-3-benzoil-benzotiofeno y de sales farmaceuticamente aceptables de los mismos para reducir el nivel de perdidasoseas, asociadas con la administracion de estrogenos.
ARP960102931A AR003002A1 (es) 1995-06-06 1996-06-05 Composiciones farmaceuticas para reducir las perdidas oseas cuando se administran esteroides y metodo para reducir dichas perdidas aplicando dichascomposiciones

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP960102931A AR003002A1 (es) 1995-06-06 1996-06-05 Composiciones farmaceuticas para reducir las perdidas oseas cuando se administran esteroides y metodo para reducir dichas perdidas aplicando dichascomposiciones

Country Status (27)

Country Link
EP (1) EP0747056B1 (es)
JP (1) JP2001501907A (es)
KR (1) KR19990022497A (es)
CN (1) CN1239429A (es)
AR (2) AR003134A1 (es)
AT (1) ATE187643T1 (es)
AU (1) AU696927B2 (es)
BR (1) BR9608390A (es)
CA (1) CA2223174A1 (es)
CO (1) CO4700447A1 (es)
CZ (1) CZ383097A3 (es)
DE (1) DE69605600T2 (es)
DK (1) DK0747056T3 (es)
EA (1) EA199800014A1 (es)
ES (1) ES2142545T3 (es)
GR (1) GR3032863T3 (es)
HU (1) HUP9900854A3 (es)
IL (1) IL118573A (es)
NO (1) NO975560L (es)
PE (1) PE2298A1 (es)
PL (1) PL323941A1 (es)
PT (1) PT747056E (es)
SI (1) SI0747056T1 (es)
TR (1) TR199701508T1 (es)
WO (1) WO1996039141A1 (es)
YU (1) YU34296A (es)
ZA (1) ZA964681B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0937145A1 (en) * 1996-11-22 1999-08-25 Akzo Nobel N.V. Bmp-4 promoter and use thereof in screening of therapeutic agents for the prevention and/or treatment of osteoporosis
GB2324726A (en) * 1997-05-01 1998-11-04 Merck & Co Inc Combination Therapy for the Treatment of Osteoporosis
US6096764A (en) * 1997-08-21 2000-08-01 Eli Lilly And Company Methods for inhibiting detrimental side-effects due to GnRH of GnRH agonist administration
US6465445B1 (en) * 1998-06-11 2002-10-15 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
US7005428B1 (en) 1998-06-11 2006-02-28 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4895715A (en) * 1988-04-14 1990-01-23 Schering Corporation Method of treating gynecomastia
US5393785A (en) * 1988-10-31 1995-02-28 Endorecherche, Inc. Therapeutic antiestrogens
US5482949A (en) * 1993-03-19 1996-01-09 Eli Lilly And Company Sulfonate derivatives of 3-aroylbenzo[b]thiophenes
DE4329344A1 (de) * 1993-08-27 1995-03-02 Schering Ag Progesteronantagonistisch- und antiöstrogen wirksame Verbindungen für die Behandlung des Leiomyomata uteri

Also Published As

Publication number Publication date
BR9608390A (pt) 1999-05-04
HUP9900854A2 (hu) 1999-08-30
PE2298A1 (es) 1998-02-28
HUP9900854A3 (en) 2000-03-28
GR3032863T3 (en) 2000-07-31
EA199800014A1 (ru) 1998-06-25
YU34296A (en) 1999-11-22
JP2001501907A (ja) 2001-02-13
CZ383097A3 (cs) 1998-09-16
NO975560D0 (no) 1997-12-02
TR199701508T1 (xx) 1998-03-21
AU696927B2 (en) 1998-09-24
CA2223174A1 (en) 1996-12-12
EP0747056A2 (en) 1996-12-11
DK0747056T3 (da) 2000-05-01
EP0747056B1 (en) 1999-12-15
DE69605600T2 (de) 2000-05-31
KR19990022497A (ko) 1999-03-25
CN1239429A (zh) 1999-12-22
AR003002A1 (es) 1998-05-27
DE69605600D1 (de) 2000-01-20
PT747056E (pt) 2000-05-31
EP0747056A3 (en) 1997-03-05
WO1996039141A1 (en) 1996-12-12
CO4700447A1 (es) 1998-12-29
IL118573A0 (en) 1996-10-16
ZA964681B (en) 1997-12-05
ATE187643T1 (de) 2000-01-15
NO975560L (no) 1998-01-26
SI0747056T1 (en) 2000-06-30
PL323941A1 (en) 1998-04-27
IL118573A (en) 2000-01-31
AU5981696A (en) 1996-12-24
ES2142545T3 (es) 2000-04-16

Similar Documents

Publication Publication Date Title
DE60039125D1 (de) 9-(piperazinylalkyl)carbazole als bax-modulatoren
AR015987A1 (es) DERIVADOS DE PLEUROMUTILINA, COMPOSICIoN FARMACÉUTICA QUE LOS CONTIENE, Y, SU USO PARA LA ELABORACIoN DE UN MEDICAMENTO.
ES2150577T3 (es) Aminoeteres aromaticos como agentes para aliviar el dolor.
ES2141957T3 (es) Uso de raloxifeno y sus analogos para la produccion de un medicamento para el tratamiento de enfermedades virales.
MX9300786A (es) Compuestos hipolipidaemicos.
UY26258A1 (es) Derivados de 8-fenil-6,9-dihidro-[1,2,4] triazolo [3,4-i] purin-5-ona.
DK0562956T3 (da) Hidtil ukendte naphthylalkylaminer, fremgangsmåde til fremstilling heraf og farmaceutiske midler, som indeholder dem
AR024145A1 (es) Derivados de 5-fenil-pirimidina
AR019053A1 (es) Uso de 2'2'-difluoronucleosidos para la preparacion de un medicamento y composicion farmaceutica y producto farmaceutico que los contienen
ES2118203T3 (es) Nuevos derivados benzopiranicos, su procedimiento de preparacion y composiciones farmaceuticas que los contienen.
DE3069813D1 (en) Pharmaceutical composition containing a diphenylhydantoin derivative, derivatives used and their preparation
CO4700446A1 (es) Procedimientos para minimizar la perdida osea
YU42397A (sh) Korišćenje raloksifena za pripremu leka
ES2108240T3 (es) Derivados de tiosemicarbazona de 2-formilpiridina, su preparacion y su uso como agentes antitumor.
AR022839A1 (es) Antagonistas de la integrina alfavbeta3 en combinacion con agentes quimioterapeuticos
AR003134A1 (es) Uso de compuestos de 2-fenil-3-benzoil-benzotiofeno y de sales farmaceuticamente aceptables de los mismos para reducir el nivel de perdidasoseas, asociadas con la administracion de estrogenos.
ES2091126T3 (es) Nuevos compuestos biciclicos de pirimidina, su procedimiento de preparacion y composiciones farmaceuticas que los contienen.
AR004691A1 (es) Nuevos derivados de [3-alcoxi-fenoxi-)-etil]-dialquilamina, una composicion farmaceutica que los comprende, su uso como anestesicos locales y unprocedimiento para su preparacion
KR960034200A (ko) 항편두통성 인돌릴알킬-피리딘일 및 피리미딘일피페라진의 1,2,5-티아디아졸 유도체
ES2078838A1 (es) Procedimiento para preparar una composicion a base de clozapina.
FI953566A0 (fi) Tahdospironia tai sen analogeja sisältäviä koostumuksia
ES2128701T3 (es) Derivados triciclicos y su uso en productos farmaceuticos.
KR960703912A (ko) 중추신경계 활성을 갖는 헤테로사이클 아민(heterocyclic amines having central nervous system activity)
DE69300296D1 (de) Thiochromanderivate, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zubereitungen.
KR900012925A (ko) 인돌 유도체

Legal Events

Date Code Title Description
FA Abandonment or withdrawal